Prediction: These 2 Stocks Will Outperform the Market Through 2030
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money in exchange-traded funds (ETFs) that track the performance of indexes like the S&P 500.However, it's possible to earn even better returns by investing in companies that can beat the market. Though it can be challenging to find such corporations, let's consider two excellent candidates: Amgen (NASDAQ: AMGN) and Intuitive Surgical (NASDAQ: ISRG).Leading drugmaker Amgen could have several growth drivers through the end of the decade. The company's lineup features key products such as Tezspire, an asthma treatment, and Tepezza, a medicine for thyroid eye disease (TED). Tezspire is still undergoing several clinical trials and should earn label expansions. Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.Continue reading
Equity markets can move every which way from one day to the next. The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by putting their money in exchange-traded funds (ETFs) that track the performance of indexes like the S&P 500.
However, it's possible to earn even better returns by investing in companies that can beat the market. Though it can be challenging to find such corporations, let's consider two excellent candidates: Amgen (NASDAQ: AMGN) and Intuitive Surgical (NASDAQ: ISRG).
Leading drugmaker Amgen could have several growth drivers through the end of the decade. The company's lineup features key products such as Tezspire, an asthma treatment, and Tepezza, a medicine for thyroid eye disease (TED). Tezspire is still undergoing several clinical trials and should earn label expansions. Tepezza remains the only treatment for TED approved in the U.S., and Amgen has also been launching it in other countries.
